The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model
Christopher Semsarian(The University of Sydney), Jonathan G. Seidman(Harvard University), Michael Giewat(Howard Hughes Medical Institute), Steven Reiken(Columbia University), Imran Ahmad(Howard Hughes Medical Institute), Dimitrios Georgakopoulos(Swinburne University of Technology), Ulrike Mende(Brown University), Bradley K. McConnell(University of Houston), Joachim P. Schmitt(Howard Hughes Medical Institute), Christine E. Seidman(Harvard University), David A. Kass(Johns Hopkins University), Andrew R. Marks(Columbia University)
Cited by 235
Related Papers
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k
Cells of the adult human heart
|Nature|2020|1.8k
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy
|Journal of the American College of Cardiology|2003|1.6k